- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01302860
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
February 28, 2017 updated by: Novartis Pharmaceuticals
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bruxelles, Belgium, 1200
- Novartis Investigative Site
-
Laeken, Belgium, 1020
- Novartis Investigative Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Novartis Investigative Site
-
-
-
-
-
Le Kremlin Bicetre, France, 94275
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany, 13353
- Novartis Investigative Site
-
Dresden, Germany, 01307
- Novartis Investigative Site
-
St. Augustin, Germany, 53757
- Novartis Investigative Site
-
Tübingen, Germany, 72076
- Novartis Investigative Site
-
-
-
-
Andalucia
-
Granada, Andalucia, Spain, 18012
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Valencia, Comunidad Valenciana, Spain, 46026
- Novartis Investigative Site
-
-
-
-
-
Lausanne, Switzerland, 1011
- Novartis Investigative Site
-
-
-
-
-
London, United Kingdom, WC1N 1EH
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 5 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients that are 28 days up to 60 months of age at the time of the screening visit.
- Body weight > or = 2.5 kg.
- Parent or legal guardian's written informed consent is required before any assessment is performed for patients.
- At study entry, patients should have a clinical diagnosis of FCAS, MWS, or NOMID and symptoms requiring pharmacological intervention. Prior agreement between the Investigator and Novartis for study eligibility is required for patients who do not have a molecular diagnosis of NALP3 mutations available (either testing not performed, or testing performed but negative) upon study entry. For those patients who have not been molecularly tested for NALP3 mutations, molecular testing should be performed during the course of the study.
- For patients treated with an IL-1 blocking agent (i.e. anakinra, rilonacept), these treatments should be discontinued prior to the baseline visit and patients must demonstrate active disease prior to treatment.
- Patients who are scheduled to receive an immunization, according to their local vaccination guidelines, with an inactivated vaccine must be willing to participate in the assessment schedule for vaccinated patients.
Exclusion Criteria:
- Preterm neonates for whom, in the Investigator's judgment, participation in the study is not deemed appropriate.
- History of recurrent and/or evidence of active bacterial, fungal, or viral infections (including HIV).
- Patients with immunodeficiency or treatment with immunosuppressive drugs.
- Live vaccinations within < or = 3 months prior to screening. No live vaccinations will be allowed throughout the course of this study and up to 3 months following the last dose.
Patients with an increased risk of tuberculosis (TB) infection according to following risk factors:
- Patients with recent close contact with persons known to have active pulmonary TB disease
- Foreign-born patients from countries with a high prevalence of tuberculosis
- Patients with recent tuberculosis infection (including children > 6 months with a positive PPD test [defined as an induration of at least 10mm])
- Patients with end-stage renal disease
- Patients with diabetes mellitus
- Patients receiving immunosuppressive therapy
- Patients with hematologic cancers.
- Participation in another trial within the last 30 days or 5 half-lives of the investigational compound (whichever is longer).
- Familial and social conditions rendering regular medical assessment not possible.
- Pediatric patients with neutropenia (absolute neutrophil count [ANC] < 1.5 x 10 to the 9th/l)
Other protocol defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Canakinumab
Canakinumab s.c.
injection (2 mg/kg) was administered every 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56
Time Frame: Week 56
|
Complete response was defined as clinical remission and serological remission.
Clinical remission was defined as Physician global assessment of auto-inflammatory disease activity as absent or minimal (using a 5-point scale ranging from absent to severe) and assessment of skin disease as absent or minimal (using a 5-point scale ranging from absent to severe).
Serological remission was defined as C reactive protein (CRP) or Serum amyloid A protein (SAA) to be less than (<) 15 milligram per liter (mg/L) and <10 mg/L respectively.
|
Week 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Aged 2 Years or Younger With at Least One Complete Response at Week 56
Time Frame: Week 56
|
Complete response was defined as clinical remission and serological remission.
Clinical remission was defined as Physician global assessment of auto-inflammatory disease activity as absent or minimal (using a 5-point scale ranging from absent to severe) and assessment of skin disease as absent or minimal (using a 5-point scale ranging from absent to severe).
Serological remission was defined as CRP or SAA to be <15 mg/L and <10 mg/L respectively.
|
Week 56
|
Percentage of Participants With Defined Grades in Physician's Global Assessment Score at Week 56
Time Frame: Week 56
|
Participants were assessed based by physician on Physician's Global Assessment measured on a 5--point scale for auto inflammatory disease activity as: 0 = None/absent; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe.
|
Week 56
|
Percentage of Participants With Defined Grades in Physician Assessment of Skin Disease at Week 56
Time Frame: Week 56
|
Participants were assessed by physician for skin disease (urticarial skin rash) measured on a 5--point scale as: 0 = None/absent; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe.
|
Week 56
|
Change From Baseline in C--Reactive Protein (CRP) and Serum Amyloid A (SAA) Concentrations at Week 56
Time Frame: Baseline, Week 56
|
The CRP and SAA were used as inflammatory markers.
The target level concentrations for CRP and SAA was ≤15 mg/L and ≤10 mg/L, respectively.
Negative change in concentration of inflammatory markers indicated improvement.
|
Baseline, Week 56
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 (start of study treatment) up to Week 56 (end of study)
|
Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen.
Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.
|
Day 1 (start of study treatment) up to Week 56 (end of study)
|
Percentage of Participants Receiving a Concomitant Vaccination During the Study
Time Frame: Day 1 (start of study treatment) to Week 56 (end of study)
|
Participants received any one of the following inactivated vaccines as per the immunization program: Corynebacterium diphtheria, Bordetella pertussis, Neisseria meningitidis, Clostridium tetani, Influenza type A, Influenza type B, Haemophilus influenza B, Streptococcus pneumoniae, or Hepatitis B were determined.
|
Day 1 (start of study treatment) to Week 56 (end of study)
|
Number of Vaccination Cases With Protective Antibody Levels Following Immunization With Inactivated Vaccines
Time Frame: Day -14 (prior-vaccination), Day 0 (vaccination), Day 28, Day 57 (post-vaccination)
|
Participants who received any inactivated vaccines during the study were assessed for their ability to attain protective antibody levels against the vaccine (antigen) post immunization.
Participants vaccinations were not assessed for a response if the antibody titre was already sufficient at pre-dose and maintained during the study.
|
Day -14 (prior-vaccination), Day 0 (vaccination), Day 28, Day 57 (post-vaccination)
|
Number of Participants With Anti-canakinumab Antibodies at Week 56
Time Frame: Week 56 (End of study)
|
Immunogenicity assessment included determination of anti-canakinumab (ACZ885) antibodies in serum samples using BIAcore system, with detection based on surface plasmon resonance technique.
|
Week 56 (End of study)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
February 22, 2011
First Submitted That Met QC Criteria
February 22, 2011
First Posted (Estimate)
February 24, 2011
Study Record Updates
Last Update Posted (Actual)
March 29, 2017
Last Update Submitted That Met QC Criteria
February 28, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
- children
- antibody
- ACZ885
- Ilaris
- Familial Cold Autoinflammatory Syndrome (FCAS)
- NLRP3
- autosomal dominant
- systemic autoinflammatory disease
- NALP-3
- familial autoinflammatory syndrome
- Cryopyrin-associated periodic syndromes (CAPS)
- Muckle-Wells Syndrome (MWS) or Neonatal Onset Multisystem Inflammatory Disease (NOMID)
- CIAS-1 gene
- human monoclonal anti-human interleukin-1 beta (IL-beta)
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Infections
- Inflammation
- Disease
- Hematologic Diseases
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Hereditary Autoinflammatory Diseases
- Skin Diseases, Genetic
- Skin Diseases, Infectious
- Leukocyte Disorders
- Suppuration
- Syndrome
- Cellulitis
- Eosinophilia
- Cryopyrin-Associated Periodic Syndromes
Other Study ID Numbers
- CACZ885D2307
- 2009-016859-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Cold Autoinflammatory Syndrome
-
Regeneron PharmaceuticalsCompletedGenetic Diseases, Inborn | Familial Cold Autoinflammatory Syndrome (FCAS) | Familial Cold Urticaria | Muckle-Wells Syndrome (MWS)United States
-
Novartis PharmaceuticalsCompletedFamilial Cold Autoinflammatory SyndromeUnited States, Germany, France
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingHypersensitivity, Immediate | Autoinflammatory Syndromes | Physical Urticaria | Familial Cold Autoinflammatory SyndromeUnited States
-
Novartis PharmaceuticalsCompletedFamilial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic SyndromesGermany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
-
Novartis PharmaceuticalsCompletedFamilial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic SyndromesJapan
-
NovartisCompletedFamilial Cold Autoinflammatory Syndrome | Cryopyrin-Associated Periodic Syndromes | Neonatal Onset Multisystem Inflammatory Disease | Muckle Wells SyndromeUnited States, Germany, Italy, Spain, United Kingdom, Turkey, France, Belgium, India
-
National Institute of Arthritis and Musculoskeletal...WithdrawnBehcet's Disease | Muckle Wells Syndrome | AutoinflammatoryUnited States
-
Nova Scotia Health AuthorityAtlantic Provinces Dermatology AssociationCompletedFamilial Cold UrticariaCanada
-
Novartis PharmaceuticalsCompletedCryopyrin-associated Periodic Syndromes (CAPS) | Familial Cold Autoinflam Syn (FCAS) | Muckle-wells Syn (MWS) | Neonatal Onset Multisystem Inflam Disease (NOMID)Switzerland, United States, Germany, Norway, Austria
-
Michael FrassCompleted
Clinical Trials on ACZ885
-
Novartis PharmaceuticalsTerminatedAbdominal Aortic Aneurysm (AAA)Denmark, United States, Netherlands, Sweden, United Kingdom
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedTNF-receptor Associated Periodic Syndromes (TRAPS)United Kingdom, Ireland, Italy
-
NovartisCompleted
-
NovartisCompletedWet Age-Related Macular DegenerationUnited Kingdom, Switzerland
-
Novartis PharmaceuticalsWithdrawnDiabetes Mellitus | Diabetes Type 1Germany, United Kingdom, United States, Canada
-
Novartis PharmaceuticalsCompletedCytokine Release Syndrome (CRS) in Patients With COVID-19-induced PneumoniaSpain, United States, United Kingdom, Russian Federation, Italy, France
-
Novartis PharmaceuticalsCompletedSickle Cell AnemiaTurkey, United States, Germany, Canada, United Kingdom, Israel, South Africa
-
Novartis PharmaceuticalsNo longer availableCytokine Release Syndrome in COVID-19-induced Pneumonia
-
Novartis PharmaceuticalsCompletedDiabetes Mellitus, Type 2 | Atherosclerosis | Prediabetic StateGermany, Israel, United States, Canada, United Kingdom